Rating Change
Citizens reiterated its Market Outperform rating on Relay Therapeutics, Inc. (NASDAQ:RLAY) on August 10, 2026.
reiterateNASDAQ:RLAY
Citizens Reiterates Market Outperform Rating on Relay Therapeutics, Inc. (RLAY)
Citizens reiterated its Market Outperform rating on Relay Therapeutics, Inc. (NASDAQ:RLAY) on August 10, 2026.
At publication ·
What changed
Relay Therapeutics, Inc. (NASDAQ:RLAY) · reiterate
- Firm
- Citizens
- Rating
- Market Outperform to Market Outperform
- Price at event
- $19.94
- Market capitalization
- $1.4B
At a glance
Key takeaways
- Citizens reiterated a Market Outperform rating on Relay Therapeutics (RLAY) on August 10, 2026, with the stock trading at $19.94 and a market capitalization of $1.4 billion.
Market Context
Relay Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $19.94 with a market capitalization of $1.4B.
Analyst coverage from Citizens provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Relay Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Relay Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 10, 2026 | Citizens | Market Outperform | N/A |
| Aug 07, 2026 | Barclays | Overweight | N/A |
| Jul 21, 2026 | Goldman Sachs | Buy | N/A |
| Jul 16, 2026 | Canaccord Genuity | Buy | N/A |
| Jul 08, 2026 | JP Morgan | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View RLAY Stock Page
Frequently Asked Questions
What does the Market Outperform rating mean for RLAY?
A rating of Market Outperform from Citizens reflects the analyst's outlook on Relay Therapeutics, Inc. (NASDAQ:RLAY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RLAY forecast page.